Yi-Ning Su

Yi-Ning Su

Auto-generated profile, based on publicly available information

Yi-Ning Su

Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2012 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Closed access
PDF file
CLC‐N Lee
C‐N Lee
SLShin-Yu Lin
Shin-Yu Lin
CLC‐H Lin
C‐H Lin
JSJ‐C Shih
J‐C Shih
TLT‐H Lin
T‐H Lin
YSY‐N Su
Y‐N Su

20 June 2008 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
SLShin-Yu Lin
Shin-Yu Lin
YSYi-Ning Su
Yi-Ning Su
CHChia-Cheng Hung
Chia-Cheng Hung
WTWoei Tsay
Woei Tsay
SCShyh-Shin Chiou
Shyh-Shin Chiou
CLChien-Nan Lee
Chien-Nan Lee
Background: Hemophilia A represents the most common and severe inherited hemorrhagic disorder. It is caused by mutations in the F8 gene, which leads to a deficiency or dysfunctional factor VIII protein, an essential cofactor in the factor X activation complex. Methods: We used long-distance polymerase chain reaction and denaturing high performance liquid chromatography for mutation scanning of the F8 gene. We designed the competitive multiplex PCR to identify the carrier with exonal deletions. In order to facilitate throughput and minimize the cost of mutation scanning, we also evaluated a new mutation scanning technique, high resolution melting analysis (HRM), as an alternative screening method. Results: We presented the results of detailed screening of 122 Taiwanese families with hemophilia A and reported twenty-nine novel mutations. There was one family identified with whole exons deletion, and the carriers were successfully recognized by multiplex PCR. By HRM, the different melting curve patterns were easily identified in 25 out of 28 cases (89%) and 15 out of 15 (100%) carriers. The sensitivity was 93 % (40/43). The overall mutation detection rate of hemophilia A was 100% in this study. Conclusion: We proposed a diagnostic strategy for hemophilia A genetic diagnosis. We consider HRM as a powerful screening tool that would provide us with a more cost-effective protocol for hemophilia A mutation identification.

5 October 2006
Verified
Journal Article
Closed access
WHWu-Shiun Hsieh
Wu-Shiun Hsieh
HWHui-Chen Wu
Hui-Chen Wu
SJSuh-Fang Jeng
Suh-Fang Jeng
HLHua-Fang Liao
Hua-Fang Liao
YSYi-Ning Su
Yi-Ning Su
PCPau-Chung Chen
Pau-Chung Chen

29 August 2003 in Human Mutation
Verified
Journal Article
Closed access
PDF file
YSYi-Ning Su
Yi-Ning Su
CLChien-Nan Lee
Chien-Nan Lee
CHChia-Cheng Hung
Chia-Cheng Hung
CCChi-An Chen
Chi-An Chen
WCWen-fang Cheng
Wen-fang Cheng
FHFon-Jou Hsieh
Fon-Jou Hsieh
Beta‐thalassemia is a common inherited disease, resulting from one or more of a total of more than 200 different mutations in the β‐globin gene (HBB). Efficient and reliable mutation‐screening methods are essential in order to establish appropriate prevention programs for at‐risk populations based upon a molecular diagnosis. We have developed a rapid and highly‐specific mutation screening test for the diagnosis of β‐thalassemia by coupling heteroduplex and primer‐extension analysis based on the denaturing high performance liquid chromatography (DHPLC) system. A total of 161 healthy heterozygous Taiwanese carriers featuring 10 different HBB mutations and 30 patients exhibiting 12 different compound heterozygous or homozygous HBB mutations were subjected to DHPLC. The elution profile for the heteroduplex analysis of DHPLC could be successfully used to identify the common disease‐causing mutations of HBB. To further confirm the sequence variants, we developed a technique combining multiplex primer‐extension analysis coupled with DHPLC for the genotyping of eight common disease‐causing mutations in the HBB gene. Overall, by coupling heteroduplex and primer‐extension analysis based upon DHPLC, we were able to unambiguously identify the most‐common β‐thalassemia mutations corresponding to more than 99% of HBB alleles among the Taiwanese population. In conclusion, compared to classic approaches to mutation screening for this malady, we suggest that DHPLC is an excellent technique to be applied to the genetic screening of prenatal and postnatal individuals as a part of a diagnosis program for β‐thalassemia and provides a more‐efficient, economic, and sensitive means to undertake such a screening program. Hum Mutat 22:326–336, 2003.

12 October 2009 in Annals of Human Genetics
Verified
Journal Article
Open access
PDF file
CHChia‐Cheng Hung
Chia‐Cheng Hung
SLShin-Yu Lin
Shin-Yu Lin
CLChien‐Nan Lee
Chien‐Nan Lee
HCHui‐Yu Cheng
Hui‐Yu Cheng
SLShuan‐Pei Lin
Shuan‐Pei Lin
YSYi‐Ning Su
Yi‐Ning Su
SUMMARY: The aim of this study was to establish a national database of mutations in the fibrillin‐1 (FBN1) gene that cause Marfan syndrome (MFS) in the Taiwanese population. In this study, we screened 294 patients from 157 families for the presence of FBN1 mutations using polymerase chain reaction/ denaturing high performance liquid chromatography (PCR/DHPLC). We identified 56 mutations in 62 of the 157 (40%) families including 49 single‐base substitutions (36 missense mutations, seven nonsense mutations, and six splicing sites), one small insertion, four small deletions, one small indel (insertion and deletion), and one exonic deletion (Exon 36). When family history was taken into consideration, the mutation detection rate rose to 91% (29 of 32). We further investigated the phenotypic data and found that one third (47 of 157) of the families fit the Ghent criteria for MFS. Based on that data, the mutation rate was 98% (46/47). That finding implies that family history and the Ghent criteria play a more important role than clinical manifestations in establishing a clinical diagnosis of Marfan syndrome. Among the 56 mutations found in this study, 40 (71%) have not been registered in the Human Gene Mutation Database (HGMD) or in the Universal Mutation Database (UMD). This is the first study of the mutation spectrum of MFS in a cohort of patients in Taiwan. The database is expected to considerably improve genetic counseling for and medical care of MFS families.

12 January 2007
Verified
Journal Article
Closed access
CHChia-Yen Huang
Chia-Yen Huang
WCWen-fang Cheng
Wen-fang Cheng
CLChien-Nan Lee
Chien-Nan Lee
YSYi-Ning Su
Yi-Ning Su
SCShu-Chin Chien
Shu-Chin Chien
CCChi-An Chen
Chi-An Chen